Glucagon challenge in patients with type 2 diabetes mellitus - Glucagon challenge T2DM

Centre for Human Drug Research0 个研究点目标入组 16 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- Type 2 diabetes mellitus controlled by oral antidiabetics (except for PPAR-gamma agents) for at least one year;
•- Age 18 to 65 years;
•- Males or females (with regular menstrual cycles if premenopausal);
•- Able and willing to provide written informed consent.

•- Use of insulin or PPAR-gamma agents;
•- Glycated hemoglobin (HbA1c) > 8%;
•- BMI <= 22 kg/m2 and >= 35 kg/m2;
•- Any evidence of cardiovascular, pulmonary, renal, hepatic or other major organ system disease as determined by history, physical examination, and routine laboratory tests;
•- Uncontrolled hypertension (systolic blood pressure >= 150 mm Hg or a diastolic blood pressure >= 95 mm Hg);
•- Use of medication known to affect glucose homeostasis (except for biguanides and sulphonylureas), anti-inflammatory drugs, non-selective beta blockers such as propranolol, oral anticoagulants, systemic glucocorticoids or other immunosuppressive drugs;
•- Use of prescription or over-the-counter drug(s) to promote weight loss;
•- Pregnancy or breastfeeding;
•- Not able or willing to use an acceptable contraceptive method for study duration for females (hormonal contraceptives, intra-uterine device or condom/pessary);
•- Not able and willing to refrain from smoking and/or xanthine use on study day;
•- Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus;
•- History of alcohol or drug abuse;
•- Undergoing or have undergone treatment with an investigational drug, biologic agent or device within 90 days prior to screening
•- Blood donation within three months and plasma donation within two weeks of screening.

发起方